TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8671151

Group type: EXPERIMENTAL
Intervention: GnRH at pulse frequency of 90 min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GnRH at pulse frequency of 120 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: GnRH at pulse frequency of 60 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: GnRH at pulse frequency of 180 min
Number of subjects: 20
Study: 1744962

Group type: EXPERIMENTAL
Intervention: HA-1A monoclonal antibody
Number of subjects: 543
Study: 6945849

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31614361

Group type: EXPERIMENTAL
Intervention: 2 doses of fosfomycin (group A)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: 3 doses of fosfomycin (group B)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Fusion biopsy
Number of subjects: 297

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 297
Study: 28122382

Group type: EXPERIMENTAL
Intervention: Migraine group
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 26649536

Group type: EXPERIMENTAL
Intervention: 8-week Internet-delivered acceptance-based cognitive behavioral therapy (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 23832310

Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Endoscopic retrograde biliary drainage (ERBD)
Number of subjects: 94
Study: 21111590

Group type: EXPERIMENTAL
Intervention: Long-term nocturnal non-invasive ventilation (NIV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Withdrawal of NIV
Number of subjects: 26
Study: 19379147

Group type: EXPERIMENTAL
Intervention: Oral hypoglycemic agents (OHAs)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Meglitinides
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Hypoglycemic patients
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-hypoglycemic patients
Number of subjects: 102
Study: 17971948

Group type: EXPERIMENTAL
Intervention: Chinese herbs treatment, administered as customized soups, taken twice daily for one week.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western medicine treatment (WM), details not specified.
Number of subjects: 0
Study: 15233285

Group type: EXPERIMENTAL
Intervention: 201Tl scintigraphy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Three-phase bone scintigraphy
Number of subjects: 30
Study: 10996353

Group type: EXPERIMENTAL
Intervention: C242T polymorphism of the p22 phox gene
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (subjects without known arterial disease)
Number of subjects: 324
Study: 9497572

Group type: EXPERIMENTAL
Intervention: p53 immunostaining in adenomas
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: p53 immunostaining in carcinomas
Number of subjects: 72

Group type: COMPARATOR
Intervention: Survival analysis based on p53 expression in cancer patients
Number of subjects: 72
Study: 8371026

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 64570

Group type: EXPERIMENTAL
Intervention: BCG vaccination (4 or more scars)
Number of subjects: 64570
Study: 3092655

Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms administered twenty minutes before each dose of aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 600 mg given over 48 hours
Number of subjects: 0
Study: 31541565

Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stromal vascular fraction-enriched platelet-rich plasma (SVF-PRP)
Number of subjects: 0
Study: 29324578

Group type: COMPARATOR
Intervention: 3× per week (n = 16)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 6× per week (n = 12)
Number of subjects: 28
Study: 27391533

Group type: EXPERIMENTAL
Intervention: BioTrue (MPS)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Clear Care (hydrogen peroxide control)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Senofilcon A
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Lotrafilcon B
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Comfilcon A
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Other SCL types
Number of subjects: 253
Study: 24816942

Group type: EXPERIMENTAL
Intervention: Emotion-potentiated startle in individuals with FXS
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Emotion-potentiated startle in individuals with DD
Number of subjects: 3

Group type: COMPARATOR
Intervention: Emotion-potentiated startle in typically developing controls
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Social avoidance in individuals with FXS
Number of subjects: 3
Study: 22210576

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 4900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4900
Study: 20136179

Group type: EXPERIMENTAL
Intervention: Consonant-oriented training group
Number of subjects: 2

Group type: COMPARATOR
Intervention: Vowel-oriented training group
Number of subjects: 2
Study: 18757653

Group type: EXPERIMENTAL
Intervention: Group 1: Monthly replacement of the ring with no ring-free days
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Group 2: Monthly replacement of the ring with a 4-day hormone-free interval if breakthrough bleeding/spotting occurred for 5 days or more
Number of subjects: 65

Group type: COMPARATOR
Intervention: 4-day hormone-free interval
Number of subjects: 65
Study: 15530590

Group type: EXPERIMENTAL
Intervention: Combined breast health/weight loss intervention
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combined breast health/weight loss intervention (Cohort 2)
Number of subjects: 64
Study: 12911203

Group type: EXPERIMENTAL
Intervention: Cato 0.51 x min(‐1) without HME (group 1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cato 1.01 x min(‐1) without HME (group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cato 0.51 x min(‐1) with HME (group 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cato 1.01 x min(‐1) with HME (group 4)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aestiva 0.51 x min(‐1) without HME (group 5)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Aestiva 1.01 x min(‐1) without HME (group 6)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aestiva 0.51 x min(‐1) with HME (group 7)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Aestiva 1.01 x min(‐1) with HME (group 8)
Number of subjects: 48
Study: 10440160

Group type: EXPERIMENTAL
Intervention: Prolonged heparin infusion (12 to 24 h) followed by sheath removal (Group 1)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Early removal of sheaths followed by reinstitution of heparin infusion for 12 to 18 h (Group 2)
Number of subjects: 414

Group type: COMPARATOR
Intervention: No further heparin after intervention with early sheath removal (Group 3)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 414
Study: 7759460

Group type: EXPERIMENTAL
Intervention: Albuterol powder 200 micrograms
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol 180 micrograms
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 2334618

Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion of morphine (mean 73.6 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous extradural infusion of 0.25% bupivacaine (mean 192 mg)
Number of subjects: 10
Study: 7458119

Group type: EXPERIMENTAL
Intervention: Prophylactic ampicillin in vaginal hysterectomies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group in abdominal hysterectomies
Number of subjects: 100
Study: 30538032

Group type: EXPERIMENTAL
Intervention: Proficiency-based laparoscopic skills training
Number of subjects: 38
Study: 29103841

Group type: EXPERIMENTAL
Intervention: Crossflow pump
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 24K pump
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Continuous Wave III pump
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Double Pump RF
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: FMS/DUO+
Number of subjects: 5
Study: 26870683

Group type: EXPERIMENTAL
Intervention: GABA-enriched white rice (11.2 mg GABA/100 g of rice)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo rice (2.7 mg GABA/100 g of rice)
Number of subjects: 39
Study: 25033925

Group type: EXPERIMENTAL
Intervention: 50,000 IU Vitamin D3 at monthly intervals
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 21577132

Group type: EXPERIMENTAL
Intervention: Iomeprol 400 at 3 mL/s (IDR = 1.2 gI/s)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iomeprol 400 at 4 mL/s (IDR = 1.6 gI/s)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Iomeprol 300 at 5.4 mL/s (IDR = 1.6 gI/s)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Iomeprol 300 at 4 mL/s (IDR = 1.2 gI/s)
Number of subjects: 100
Study: 20399996

Group type: EXPERIMENTAL
Intervention: Dispersible tablet formulation of ampicillin/probenecid (1500 mg total; 250 mg each containing ampicillin 194.5 mg and probenecid 55.5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Branded capsule formulation of ampicillin/probenecid (1500 mg total; 250 mg each containing ampicillin 194.5 mg and probenecid 55.5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study: 18061070

Group type: EXPERIMENTAL
Intervention: GTN treatment for 48 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (nontolerant vessels)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Incubation of control venous vessels with GTN
Number of subjects: 50
Study: 15683530

Group type: EXPERIMENTAL
Intervention: Pulse duration of 0.2 ms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pulse duration of 1.0 ms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pulse duration of 0.2 ms vs 1.0 ms
Number of subjects: 20
Study: 11889152

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3
Study: 9806691

Group type: EXPERIMENTAL
Intervention: Intraarticular triamcinolone acetonide 10 mg in isotonic saline 20 mL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline 20 mL
Number of subjects: 60
Study: 7696069

Group type: EXPERIMENTAL
Intervention: Patient-controlled extradural analgesia (PCEA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patient-controlled i.v. analgesia (PCIVA)
Number of subjects: 40
Study: 2654207

Group type: EXPERIMENTAL
Intervention: Polidocanol 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polidocanol 0.50%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polidocanol 0.75%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polidocanol 1.0%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polidocanol 0.25%, 0.50%, 0.75%, 1.0%
Number of subjects: 0
Study: 337493

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate 1.0 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (larger doses)
Number of subjects: 0
Study: 6797733

Group type: EXPERIMENTAL
Intervention: Nitroglycerine
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 31
Study: 30782672

Group type: EXPERIMENTAL
Intervention: Group Metacognitive Grief Therapy (MCGT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 22
Study: 29522530

Group type: EXPERIMENTAL
Intervention: Family Clinic Day (FCD) intervention
Number of subjects: 2679

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2679
Study: 27394187

Group type: EXPERIMENTAL
Intervention: Massive cerebrospinal fluid (CSF) replacement (CR group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Regular therapy alone (C group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study: 24553103

Group type: EXPERIMENTAL
Intervention: Paretic‐No Mirror
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Nonparetic‐Mirror
Number of subjects: 93

Group type: COMPARATOR
Intervention: Nonparetic‐No Mirror
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bilateral‐Screen
Number of subjects: 93

Group type: COMPARATOR
Intervention: Bilateral‐Mirror
Number of subjects: 93
Study: 22916192

Group type: EXPERIMENTAL
Intervention: PCV-7 vaccine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Serogroup C meningococcal conjugate vaccine
Number of subjects: 200
Study: 20466791

Group type: EXPERIMENTAL
Intervention: Informed choice invitation
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Standard invitation
Number of subjects: 1272
Study: 17545497

Group type: EXPERIMENTAL
Intervention: Decision-maker perspective
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: Pressure to make a decision
Number of subjects: 2400
Study: 15846268

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 125

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 125
Study: 12063103

Group type: EXPERIMENTAL
Intervention: Patient responses to HRQOL measures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proxy responses to HRQOL measures
Number of subjects: 0
Study: 9707054

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg b.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no ranitidine)
Number of subjects: 20
Study: 7497050

Group type: EXPERIMENTAL
Intervention: Prototype esophageal detection device (EDD)
Number of subjects: 51
Study: 2122630

Group type: EXPERIMENTAL
Intervention: L-carnitine 10 mg/kg (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline (n = 6)
Number of subjects: 12
Study: 366182

Group type: EXPERIMENTAL
Intervention: 50 mg intravenous indomethacin
Number of subjects: 47

Group type: COMPARATOR
Intervention: 5 mg intravenous riboflavin (placebo)
Number of subjects: 47
Study: 31627177

Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 29902418

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 50
Study: 26566950

Group type: EXPERIMENTAL
Intervention: Simple telephone reminder (TEL)
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Telephone support (TEL-SUPP)
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Telephone support plus anticipated regret (TEL-SUPP-AR)
Number of subjects: 856

Group type: COMPARATOR
Intervention: No telephone call (control)
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Intervention participants (per protocol analysis)
Number of subjects: 856
Study: 24341324

Group type: EXPERIMENTAL
Intervention: TPVB plus IV PCA
Number of subjects: 34

Group type: COMPARATOR
Intervention: IV PCA alone
Number of subjects: 34
Study: 23312888

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus paclitaxel (10 mg/kg on days 1 and 15; 90 mg/m² on days 1, 8, and 15, every 4 weeks)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 564

Group type: COMPARATOR
Intervention: Bevacizumab plus capecitabine (15 mg/kg on day 1; 1000 mg/m² twice daily on days 1-14, every 3 weeks)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Bevacizumab plus capecitabine
Number of subjects: 564
Study: 20216027

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided regional anesthesia (UGRA)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard nerve localization tools
Number of subjects: 500
Study: 18816591

Group type: EXPERIMENTAL
Intervention: Quantitative muscle testing (QMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional activities assessment (FAA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulmonary function testing (PFT)
Number of subjects: 0
Study: 15722700

Group type: EXPERIMENTAL
Intervention: Intensive telephone follow-up (12 weekly phone calls)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Control group (standard disease management program without intensive telephone follow-up)
Number of subjects: 507
Study: 12823593

Group type: EXPERIMENTAL
Intervention: 1.0 microg/kg peginterferon‐alpha‐2b twice weekly for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1.0 microg/kg peginterferon‐alpha‐2b once weekly for 4 weeks
Number of subjects: 10
Study: 10910848

Group type: EXPERIMENTAL
Intervention: ondansetron (4 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: droperidol (0.625 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 9013368

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 455

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 455
Study: 8237746

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (12,500 units subcutaneously every 12 hours for three doses after sheath removal)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Intravenous heparin (1000 units/hour for 12 to 18 hours)
Number of subjects: 151
Study: 3548987

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 38

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 38
Study: 28488924

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 10
Study: 27149489

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus before sedation, continuous infusion at 2 mg/kg/h during sedation)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (normal saline, same bolus and infusion volumes as lidocaine)
Number of subjects: 66
Study: 25304475

Group type: EXPERIMENTAL
Intervention: Continuous right thoracic paravertebral block with 10-mL bolus of 0.2% ropivacaine followed by continuous infusion of 6 mL/h for 24 hours (PVB group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline administered through the same catheter scheme (control group)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Continuous right thoracic paravertebral block (PVB group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 48
Study: 22860302

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg x kg(‐1) on induction)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sevoflurane (5% inspired concentration)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 13
Study: 19545320

Group type: EXPERIMENTAL
Intervention: Instructions associated with the home use of a disclosing agent (1% neutral red)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral and denture hygiene instructions
Number of subjects: 32

Group type: COMPARATOR
Intervention: Follow‐up only (control)
Number of subjects: 32
Study: 18467544

Group type: EXPERIMENTAL
Intervention: Nutrient supplement (protein, carbohydrate, calcium, and vitamin D)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 15690254

Group type: EXPERIMENTAL
Intervention: Evidence-based moderated case discussions delivered via e-mail
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 58
Study: 12633127

Group type: EXPERIMENTAL
Intervention: Integrated family and individual therapy (IFIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard community care (CM)
Number of subjects: 30
Study: 12892048

Group type: EXPERIMENTAL
Intervention: Vitamin E (1600 IU/d)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 8550792

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 2 IU/m2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Insulin-like Growth Factor I (IGF‐I) 80 micrograms/kg
Number of subjects: 12
Study: 1801154

Group type: EXPERIMENTAL
Intervention: Amocarzine 3 mg/kg oral dose twice daily for three days (fed patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Amocarzine 3 mg/kg oral dose twice daily for three days (fasting patients)
Number of subjects: 20
Study: 6861446

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Adrenaline
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30796027

Group type: EXPERIMENTAL
Intervention: Hypomethylation of cg08309687 (LINC00649)
Number of subjects: 4525

Group type: EXPERIMENTAL
Intervention: 22 CpGs associated with hepatic fat in EA participants
Number of subjects: 4525
Study: 29874535

Group type: EXPERIMENTAL
Intervention: Mifepristone pretreatment (200 mg orally) followed by misoprostol (800 μg vaginally)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Misoprostol alone (800 μg vaginally)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mifepristone pretreatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 300
Study: 27095698

Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA group; n=20) plus standard care
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard care only (control group, n=18)
Number of subjects: 38
Study: 24767003

Group type: EXPERIMENTAL
Intervention: Scopolamine (4ug/kg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 22647753

Group type: EXPERIMENTAL
Intervention: Prediabetic individuals
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Family history of diabetes, blood pressure, waist, high-density lipoprotein cholesterol, and FPG
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Family history of premature CVD, waist, and FPG
Number of subjects: 1372
Study: 20231764

Group type: EXPERIMENTAL
Intervention: Respondents to the initial mailed screener
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Eligible individuals
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Enrolled individuals
Number of subjects: 1049